Contraindicated (1)pentobarbital will lessen the extent or influence of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the extent or result of methadone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
네덜란드의 경우, 의사조력 자살의 표준 프로토콜은 정맥주사로 티오펜탈 마취를 한후, 브롬화물이나 알크로늄, 혹은 판큐로늄브롬화물을 주입하여 호흡기를 정지시킨다.
pentobarbital will lower the level or effect of gefitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital decreases amounts of elvitegravir/cobicistat/emtricitabine/tenofovir DF by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May cause loss of virologic reaction and doable resistance.
pentobarbital will reduce the extent or influence of indinavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will minimize the level or result of carbamazepine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will lower the level or impact of zonisamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Not known.
pentobarbital decreases effects of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Carefully. Coadministration of CYP3A4 inducers may lower sufentanil concentrations and efficacy, maybe precipitating withdrawal syndrome in patients that have created Bodily dependence to sufentanil. Discontinuation of concomitantly made use of CYP3A4 inducers may increase sufentanil plasma concentration.
Contraindicated (1)pentobarbital will minimize the level or impact of lumacaftor/ivacaftor by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or impact of zolpidem by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.
pentobarbital will lower the level or effect of apremilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong CYP inducers brings about an important lower of systemic publicity of apremilast, which may result in lack of efficacy
Parenteral methods of barbiturates are remarkably alkaline; Serious treatment must be taken in order to avoid perivascular extravasation or intra-arterial injection; extravascular injection could result in nearby tissue damage with subsequent necrosis; consequences of intra-arterial injection may perhaps differ from transient discomfort to gangrene on the limb; any grievance of pain during the limb warrants halting the injection
Observe Closely (1)pentobarbital will minimize the level or impact of fentanyl transmucosal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers may lead to your minimize in fentanyl plasma concentrations, insufficient efficacy or, potentially, development of a withdrawal syndrome in the affected individual who has created Bodily dependence to fentanyl. check here Soon after halting a CYP3A4 inducer, given that the effects from the inducer decline, the fentanyl plasma concentration will boost which could enhance or lengthen both the therapeutic and adverse effects.